Dr. Fedyanin on Future Treatment Landscape of CRC

Mikhail Fedyanin, MD, PhD
Published: Monday, Dec 19, 2016



Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses future approaches for the treatment of patients with colorectal cancer (CRC).

There will hopefully be more novel agents approved in the CRC space, Fedyanin explains, such as combination regimens of MEK inhibitors and PD-1 inhibitors. Additionally, he predicts and anticipates more research dedicated to treatments for patients with CRC who harbor KRAS mutations. Currently, there are a lack of effective agents able to target this patient population. 


Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses future approaches for the treatment of patients with colorectal cancer (CRC).

There will hopefully be more novel agents approved in the CRC space, Fedyanin explains, such as combination regimens of MEK inhibitors and PD-1 inhibitors. Additionally, he predicts and anticipates more research dedicated to treatments for patients with CRC who harbor KRAS mutations. Currently, there are a lack of effective agents able to target this patient population. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x